Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? [Yahoo! Finance]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Yahoo! Finance
According to some fresh clinical data from Regenxbio (NASDAQ: RGNX) , another biotech, the company is making headway with a gene therapy for Duchenne muscular dystrophy (DMD), the condition that's Sarepta's focus. Does an upcoming new player on the scene pose a big-enough threat to Sarepta to justify selling the stock today? The answer is a bit more complicated than merely "no," so let's dive in and clarify the issue. A new competitor looks to find a niche Regenxbio's gene therapy program is called RGX-202, and it could provide a measure of long-lasting relief to patients with DMD. The concept of RGX-202, as well as Sarepta's Elevidys therapy, is to replace the dysfunctional copies of a patient's disease-related genes with synthetically designed functional versions, such that when those genes are expressed by cells, the correct protein is produced rather than a dysfunctional version. Then the patient's symptoms, like muscle weakness and mobility issues, hopefully start to abate.
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitPR Newswire
- REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures [Yahoo! Finance]Yahoo! Finance
- REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $40.00 price target on the stock.MarketBeat
- REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
RGNX
Earnings
- 2/27/24 - Miss
RGNX
Sec Filings
- 4/17/24 - Form 4
- 4/4/24 - Form ARS
- 4/4/24 - Form DEFA14A
- RGNX's page on the SEC website